AMAR On Other Exchanges
Symbol
Exchange
OTC US

amarillo biosciences inc (AMAR) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AMARILLO BIOSCIENCES INC (AMAR)
\

Related News

No related news articles were found.

amarillo biosciences inc (AMAR) Related Businessweek News

No Related Businessweek News Found

amarillo biosciences inc (AMAR) Details

Amarillo Biosciences, Inc. engages in the development of biologics for the treatment of human and animal diseases. The company owns or licenses five issued patents related to the low-dose oral delivery of interferon; and owns one issued patent on its dietary supplement, Maxisal. It focuses on research for the treatment of human disease indications primarily influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon alpha. Amarillo Biosciences, Inc. was founded in 1984 and is based in Amarillo, Texas.

4 Employees
Last Reported Date: 04/16/19
Founded in 1984

amarillo biosciences inc (AMAR) Top Compensated Officers

Chairman of the Board, CEO, President, CFO & ...
Total Annual Compensation: $340.0K
Vice President of Administration
Total Annual Compensation: $82.0K
Compensation as of Fiscal Year 2018.
amarillo biosciences inc
Amarillo Biosciences, Inc. announced delayed 10-Q filing

On 05/10/2019, Amarillo Biosciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

Amarillo Biosciences, Inc. Announces Retirement of Edward L. Morris as Director, General Counsel, and Corporate Secretary, Effective April 30, 2019

Edward L. Morris has given notice of his retirement, effective April 30, 2019, from all his positions with the Amarillo Biosciences, Inc., including director, general counsel, and corporate secretary.

Amarillo Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2018

Amarillo Biosciences, Inc. announced earnings results for the full year ended December 31, 2018. For the full year, the company announced sales was USD 77,724 compared to USD 250,928 a year ago. Operating loss was USD 1.334 million compared to USD 579,763 a year ago. Net loss was USD 1.338 million compared to USD 617,375 a year ago. Basic loss per share from continuing operations was USD 0.04 compared to USD 0.03 a year ago.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

AMAR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AMAR.
View Industry Companies
 

Industry Analysis

AMAR

Industry Average

Valuation AMAR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 506.2x
Price/Book 23.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 451.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact AMARILLO BIOSCIENCES INC, please visit www.amarbio.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.